AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7844059 — intervention group
Group type: COMPARATOR
Intervention: Massed-reinforcement (food) control
Number of subjects: 4
Study 7844059 — intervention group
Group type: COMPARATOR
Intervention: No-reinforcement control
Number of subjects: 4
Study 2967830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 30
Study 2967830 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 30
Study 29549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg bolus followed by 0.2-0.7 μg/kg/h infusion from induction of anesthesia to the end of surgery (group D1)
Number of subjects: 354
Study 29549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg bolus (group D2)
Number of subjects: 354
Study 29549829 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 354
Study 27052531 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid 400 μg/d
Number of subjects: 605
Study 27052531 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid 800 μg/d
Number of subjects: 605
Study 27052531 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine 3 g/d
Number of subjects: 605
Study 27052531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 25768068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training on an instrumented treadmill with biofeedback, biweekly for 3 months
Number of subjects: 56
Study 25768068 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 56
Study 23111138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 60
Study 23111138 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg/day
Number of subjects: 60
Study 23111138 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 60
Study 23111138 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 60
Study 23111138 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 60
Study 20935604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope®
Number of subjects: 44
Study 20935604 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 44
Study 19394790 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 84
Study 19394790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg b.i.d. (after 9 doses of 200 mg q.i.d.)
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg b.i.d. (after 9 doses of 400 mg q.i.d.)
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg q.d. (after 5 doses of 800 mg b.i.d.)
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean exposure of 400 mg b.i.d.
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (BMT) recipients
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 98
Study 16436724 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events leading to premature discontinuation
Number of subjects: 98
Study 15545238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic asymmetric fitted sock
Number of subjects: 16
Study 15545238 — intervention group
Group type: COMPARATOR
Intervention: Standard running sock
Number of subjects: 16
Study 11704101 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-day EE/GSD
Number of subjects: 890
Study 11704101 — intervention group
Group type: COMPARATOR
Intervention: 21-day EE/DSG
Number of subjects: 890
Study 11704101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 890
Study 9422908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 2 mg
Number of subjects: 90
Study 9422908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular clonidine 150 micrograms
Number of subjects: 90
Study 9422908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and clonidine
Number of subjects: 90
Study 9422908 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline solution)
Number of subjects: 90
Study 8425242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg iv (RANIV group)
Number of subjects: 60
Study 8425242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg im (RANIM group)
Number of subjects: 60
Study 8425242 — intervention group
Group type: COMPARATOR
Intervention: Placebo iv (PLAC group)
Number of subjects: 60
Study 3277372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 intravenously every 21 days combined with razoxane 750 mg/m2 weekly
Number of subjects: 9
Study 3277372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 intravenously every 21 days combined with razoxane 1150 mg/m2 weekly
Number of subjects: 9
Study 30321774 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 61
Study 30321774 — intervention group
Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 61
Study 28856580 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 1932
Study 28856580 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 1932
Study 28856580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Brivaracetam)
Number of subjects: 1932
Study 28856580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Levetiracetam)
Number of subjects: 1932
Study 26552352 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) effervescent tablets, daily dose based on weight, for 5 days
Number of subjects: 70
Study 26552352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23299767 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg · kg(‐1) body weight, n = 17)
Number of subjects: 33
Study 23299767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 23299767 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 33
Study 16642619 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture plus general anesthesia
Number of subjects: 52
Study 16642619 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 52
Study 12790816 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gum elastic bougie with nasendoscope
Number of subjects: 40
Study 12790816 — intervention group
Group type: COMPARATOR
Intervention: Standard gum elastic bougie without nasendoscope
Number of subjects: 40
Study 12790816 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal curve bougie with nasendoscope
Number of subjects: 40
Study 12790816 — intervention group
Group type: COMPARATOR
Intervention: Optimal curve bougie without nasendoscope
Number of subjects: 40
Study 10549459 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90
Study 10549459 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 90
Study 7754482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 7754482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2344697 — intervention group
Group type: EXPERIMENTAL
Intervention: D-propranolol (120 mg for 5 days)
Number of subjects: 40
Study 2344697 — intervention group
Group type: COMPARATOR
Intervention: L-propranolol (120 mg for 5 days)
Number of subjects: 40
Study 6102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% saline
Number of subjects: 359
Study 6102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% saline
Number of subjects: 359
Study 31432287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Bio‐A biosynthetic stripe (Gore) in a sub‐lay position
Number of subjects: 100
Study 31432287 — intervention group
Group type: COMPARATOR
Intervention: Standard closure in double layer using PDS 0
Number of subjects: 100
Study 29880779 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar M400 smartwatches and Facebook group with PA tips
Number of subjects: 30
Study 29880779 — intervention group
Group type: COMPARATOR
Intervention: Facebook group only (comparison group)
Number of subjects: 30
Study 29880779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and comparison)
Number of subjects: 30
Study 28274276 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline for 24 weeks
Number of subjects: 30
Study 28274276 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 30
Study 26269653 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings at systolic blood pressure of 135 to 144 mm Hg
Number of subjects: 3627
Study 26269653 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings at diastolic blood pressure of 80 to 89 mm Hg
Number of subjects: 3627
Study 26269653 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings with pulse pressure of 80 to 89 mm Hg
Number of subjects: 3627
Study 24113042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg or 5 mg once daily for 12 weeks
Number of subjects: 15
Study 21958884 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS (Rev.1.1, Abbott Vascular)
Number of subjects: 56
Study 18261199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol method
Number of subjects: 86
Study 18261199 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O method
Number of subjects: 86
Study 16034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1846
Study 16034469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1846
Study 16034469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1846
Study 12907410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient-fortified complementary food
Number of subjects: 0
Study 10577447 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg candoxatril twice a day
Number of subjects: 30
Study 10577447 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg candoxatril twice a day
Number of subjects: 30
Study 10577447 — intervention group
Group type: COMPARATOR
Intervention: 20 mg frusemide twice a day
Number of subjects: 30
Study 10577447 — intervention group
Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 30
Study 10577447 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril
Number of subjects: 30
Study 8984582 — intervention group
Group type: EXPERIMENTAL
Intervention: Guarana
Number of subjects: 45
Study 8984582 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 45
Study 8984582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1752290 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg kg‐1 h‐1)
Number of subjects: 10
Study 1752290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1752290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (2 g ursodeoxycholic acid plus 2 g chenodeoxycholic acid)
Number of subjects: 10
Study 1752290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes (4.2 g pancreatin)
Number of subjects: 10
Study 7005678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (15 to 20 mg per day, maintenance dosage 10 mg per day)
Number of subjects: 51
Study 31844133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) training
Number of subjects: 148
Study 31844133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm muscle training
Number of subjects: 148
Study 31844133 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Number of subjects: 148
Study 31844133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 148
Study 27720613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.1μg/kg/min
Number of subjects: 85
Study 27720613 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine 0.05μg/kg/min
Number of subjects: 85
Study 27720613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100μg
Number of subjects: 85
Study 27720613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 5mg
Number of subjects: 85
Study 27720613 — intervention group
Group type: EXPERIMENTAL
Intervention: Emesis incidence
Number of subjects: 85
Study 27720613 — intervention group
Group type: COMPARATOR
Intervention: Hemodynamic parameters (heart rate, incidence of bradycardia, blood pressure, cardiac output, cardiac index, stroke volume, systemic vascular resistance, neonatal outcome)
Number of subjects: 85
Study 25896832 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone-bacitracin-colistin eardrops
Number of subjects: 230
Study 25896832 — intervention group
Group type: COMPARATOR
Intervention: oral amoxicillin-clavulanate suspension
Number of subjects: 230
Study 25896832 — intervention group
Group type: COMPARATOR
Intervention: initial observation
Number of subjects: 230
Study 24239881 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1500 pulses; 1Hz; 90% of resting motor threshold for the first dorsal interosseous muscle) + Physical Therapy (PT)
Number of subjects: 20
Study 24239881 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation + Physical Therapy (PT)
Number of subjects: 20
Study 22923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Number of subjects: 1063
Study 22923753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 2 weeks)
Number of subjects: 1063
Study 22923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1063
Study 19947137 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 48
Study 19947137 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 48
Study 17553447 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic intraocular lens (AMO Sensar; AR40e)
Number of subjects: 100
Study 17553447 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lens (ClariFlex)
Number of subjects: 100
Study 15367197 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-BBM group
Number of subjects: 34
Study 15367197 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA-BBM group
Number of subjects: 34
Study 15367197 — intervention group
Group type: COMPARATOR
Intervention: Access flap procedure (AFP) group
Number of subjects: 34
Study 15367197 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between barrier groups (Collagen vs PLA)
Number of subjects: 34
Study 11262536 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 40
Study 9834045 — intervention group
Group type: EXPERIMENTAL
Intervention: N-0861 (specific doses administered via bolus and maintenance infusion)
Number of subjects: 19
Study 7867873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, once daily)
Number of subjects: 0
Study 7867873 — intervention group
Group type: COMPARATOR
Intervention: Slow-release nifedipine (20 mg, twice daily)
Number of subjects: 0
Study 2768542 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (4-16 mg/day)
Number of subjects: 90
Study 2768542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (100-175 mg/day)
Number of subjects: 90
Study 2768542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 797593 — intervention group
Group type: EXPERIMENTAL
Intervention: Daktacort cream
Number of subjects: 63
Study 797593 — intervention group
Group type: COMPARATOR
Intervention: miconazole 2%
Number of subjects: 63
Study 797593 — intervention group
Group type: COMPARATOR
Intervention: hydrocortisone 1%
Number of subjects: 63
Study 29528689 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Cognitive Stimulation Therapy (MCST)
Number of subjects: 48
Study 29528689 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 48
Study 28042732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0
Study 28042732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0
Study 26618457 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate-collagen filler
Number of subjects: 1008
Study 26618457 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaires
Number of subjects: 1008
Study 21246281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher religiosity cohort (38 patients)
Number of subjects: 87
Study 21246281 — intervention group
Group type: COMPARATOR
Intervention: Lower religiosity cohort (49 patients)
Number of subjects: 87
Study 21246281 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with higher religiosity
Number of subjects: 87
Study 22049162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake ranging from 15 to 240 mg · kg(‐1) · d(‐1)
Number of subjects: 21
Study 19590022 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (4 microg/kg/d) for 8 days
Number of subjects: 38
Study 19590022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19590022 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 38
Study 16816068 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day
Number of subjects: 350
Study 16816068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 16816068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 350
Study 12624289 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis after repetitive flexion-extension of the last 4 fingers of the right hand in migraine patients
Number of subjects: 30
Study 12624289 — intervention group
Group type: COMPARATOR
Intervention: fMRI analysis in healthy volunteers
Number of subjects: 30
Study 12624289 — intervention group
Group type: EXPERIMENTAL
Intervention: Histogram analysis of normal-appearing WM in migraine patients
Number of subjects: 30
Study 12624289 — intervention group
Group type: COMPARATOR
Intervention: Histogram analysis of normal-appearing WM in healthy volunteers
Number of subjects: 30
Study 11707785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-injection technique (group 3N)
Number of subjects: 100
Study 11707785 — intervention group
Group type: COMPARATOR
Intervention: 2-injection technique (group 2N)
Number of subjects: 100
Study 8961683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (single dose prophylactic)
Number of subjects: 0
Study 8961683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1461620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg and 1,600 mg)
Number of subjects: 0
Study 1461620 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg)
Number of subjects: 0
Study 4000864 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental subjects performing 45 trials in their respective training conditions (weight, distance, weight/distance)
Number of subjects: 203
Study 4000864 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study 30342257 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Champions for Change (WCC) and Wellness Champions for Change-Student (WCC-S)
Number of subjects: 1080
Study 30342257 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Champions for Change (WCC) only
Number of subjects: 1080
Study 30342257 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (Control)
Number of subjects: 1080
Study 27651226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 872
Study 27651226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 872
Study 27651226 — intervention group
Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 872
Study 27651226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 872
Study 24899557 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐to‐one oral instruction strategy combined with an information sheet
Number of subjects: 60
Study 24899557 — intervention group
Group type: COMPARATOR
Intervention: Regular care following admission
Number of subjects: 60
Study 22211669 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically delivered prescriptions
Number of subjects: 454
Study 22211669 — intervention group
Group type: COMPARATOR
Intervention: Standard written prescriptions
Number of subjects: 454
Study 20406780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated non-SHBG bound oestradiol in girls
Number of subjects: 663
Study 20406780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated non-SHBG bound testosterone in boys
Number of subjects: 663
Study 20406780 — intervention group
Group type: COMPARATOR
Intervention: Assay measured non-SHBG bound oestradiol in girls
Number of subjects: 663
Study 20406780 — intervention group
Group type: COMPARATOR
Intervention: Assay measured non-SHBG bound testosterone in boys
Number of subjects: 663
Study 18547419 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression treatment with special dressings
Number of subjects: 15
Study 18547419 — intervention group
Group type: COMPARATOR
Intervention: Compression treatment with low‐adherence dressings and acupuncture
Number of subjects: 15
Study 16205441 — intervention group
Group type: EXPERIMENTAL
Intervention: I.E.M. Mobilograph monitor
Number of subjects: 250
Study 16205441 — intervention group
Group type: COMPARATOR
Intervention: Spacelabs 90207 monitor
Number of subjects: 250
Study 11872893 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive and anticoagulant therapy
Number of subjects: 18